Drug Trial Radar · NCT06340568
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Jun 10, 2025
Primary completion
Mar 2028
Study completion Nov 2029
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- DualityBio Inc.; BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- First posted
- Apr 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel \[or docetaxel, if participants cannot take paclitaxel\]) works by determining the progression-free survival (PFS) of participants who have been previously treated with immune checkpoint inhibitors (ICIs). In Cohort 2, the main goal is to assess how well BNT323 works by determining the objective response rate (ORR), that is, the percentage of participants whose tumor shrinks (partial response) or disappears (complete response) after treatment. The safety of BNT323 will also be assessed by following the occurrence of unfavorable/adverse effects that are seen after treatment. Other measures include the pharmacokinetics of BNT323 (or how BNT323 moves through and out of the body), the body's immune response, and the impact on quality of life.
Conditions
- Endometrial Cancer
Interventions
BNT323/DB-1303Drug
intravenous (IV) infusion
DoxorubicinDrug
IV bolus or infusion
PaclitaxelDrug
IV infusion
DocetaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: PFS assessed by blinded independent central review (BICR) in participants with HER2 IHC 1+/2+ recurrent endometrial cancerTime frame: Up to approximately 53 months
- Cohort 2: ORR assessed by BICR in participants with HER2 IHC 3+ recurrent endometrial cancerTime frame: Up to approximately 53 months
Locations
214 sites in 27 countries. Site status is shown where the registry gives one.
USC/Norris Cancer Center
Los Angeles, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Broward Health Medical Center
Fort Lauderdale, Florida · Recruiting
OSF Saint Francis Medical Center
Peoria, Illinois · Recruiting
Carle Cancer Institute
Urbana, Illinois · Recruiting
Baptist Health Lexington
Lexington, Kentucky · Recruiting
WK Cancer Center
Shreveport, Louisiana · Recruiting
Minnesota Oncology
Minneapolis, Minnesota · Recruiting
The Center of Hope Reno
Reno, Nevada · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
SUNY Upstate Medical University
Syracuse, New York · Recruiting
Miami Valley Hospital South
Centerville, Ohio · Recruiting
Ohio State University
Hilliard, Ohio · Recruiting
Peggy & Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma · Recruiting
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania · Recruiting
Sanford Cancer Center
Sioux Falls, South Dakota · Recruiting
Texas Oncology, P.A.
Tyler, Texas · Recruiting
Intermountain Healthcare
Murray, Utah · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Centro de Oncologia Dr. Doreski - Fundación Respirar
Buenos Aires, Argentina · Recruiting
Centro de Investigaciones Medicas Mar del Plata
Buenos Aires, Argentina · Recruiting
Hospital Británico de Buenos Aires
Buenos Aires, Argentina · Recruiting
CEMAIC - Centro Medico Privado
Córdoba, Argentina · Recruiting
Investigaciones CORI S.R.L.
La Rioja, Argentina · Recruiting
COIR Fundacion Centro Oncologi, de Integracion Regional
Mendoza, Argentina · Recruiting
Fundación Oncológica Mendoza
Mendoza, Argentina · Recruiting
Hospital Provincial del Centenario
Rosario, Argentina · Recruiting
Centro Oncológico de Excelencia
San Juan, Argentina · Recruiting
Clinica Mayo de Urgencias
San Miguel de Tucumán, Argentina · Recruiting
Adelaide Oncology & Haematology
Adelaide, Australia · Recruiting
Cancer Research SA
Adelaide, Australia · Recruiting
Monash Health Clinical Trial Center
Clayton, Australia · Recruiting
Gosford Hospital
Gosford, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
Frankston Hospital
Melbourne, Australia · Recruiting
Shoalhaven Cancer Care Centre
Nowra, Australia · Recruiting
Sunshine Hospital
Saint Albans, Australia · Recruiting
Showing 40 of 214 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.